Scholar Rock takes apitegromab beyond SMA with 60-patient FSHD trial and new FDA designations
Scholar Rock has started dosing in the 60-patient Phase 2 FORGE trial of apitegromab in facioscapulohumeral muscular dystrophy after receiving FDA Fast Track and Orphan Drug designations.